HYDERABAD: Despite posting record revenues, pharma major Dr Reddy’s Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at Rs 1414.3 crore as compared to Rs 1,379 crore in the corresponding quarter of last fiscal year.
The company posted a 16% jump in revenues at nearly Rs 8,359 crore for Q3FY25 as against around Rs 7,215 crore in Q3FY24 thanks in part to a Rs 605 crore revenue boost provided to Europe business by the nicotine replacement therapy business of Haleon Plc acquired in the first quarter of FY25.
Revenues from global generics rose 17% to Rs 7,375 crore during the quarter from Rs 6,309.5 crore in Q3FY24 with the European market accounting for a 143% jump from Rs 497 crore in Q3FY24 to Rs 1209.6 crore in Q3FY25 thanks to NRT.
However, revenues from the North American market, which accounted for a chunk of overall global generics revenues, slid 1% to Rs 3383 crore in Q3FY25 from Rs 3349 crore in the same quarter of FY24.
The company’s revenues from the Indian market rose 14% to Rs 1346 crore as against Rs 1180 crore in Q3FY24 and that from emerging markets grew 12% to Rs 1436 crore from Rs 1283 crore.
Dr Reddy’s co-chairman & managing director GV Prasad attributed the double digit growth to the newly acquired NRT business, new launches and improved operational efficiencies.
